The size of the Middle East & Africa aptamers market is forecasted to be worth USD 14.3 million in 2023 and USD 17.59 million by the end of 2028, growing at a CAGR of 4.23% from 2023 to 2028.
The Aptamers market in MEA is projected to be fuelled by the increasing trend of R&D investments in pharmaceutical and biotechnology industries, technological advancements in Aptamers, and the growing prevalence of life-threatening diseases across the region. Also, the patent expiry of SELEX (systematic creation of ligands by exponential improvement technology) and the low price and great productivity of aptamers in binding to big molecules associated with antibodies are driving the market growth.
In Addition, the increasing investment and funding by the government and private organizations for developing healthcare infrastructure and research activities are enabling new market entrants and key players to introduce their new aptamer services for different applications expected to expand the market growth. Furthermore, diseases such as cardiovascular, neurodegenerative, and acquired immunodeficiency syndrome are the major factors influencing the demand for new and effective detection assays based on aptamer therapy.
The demand for the new diagnostic assay and increasing research activity in emerging markets such as South Africa, UAE, and Saudi Arabia uplifts regional market growth. In addition, efforts by many prominent players to create novel aptamers for research and development applications are significant drivers driving this segment's dominance. Because of its unique chemical characteristics, the Autobody technology requires less development time and provides effective Adsorption, Distribution, Metabolism, and Excretion (ADME) qualities.
However, unfavorable reimbursement policies and a lack of awareness about the Aptamers are limiting the market growth. Also, incomplete regulatory policies and a lack of understanding about aptamers and technical expertise may restrain the overall MEA market growth.
This research report has been segmented and sub-segmented the Middle East & Africa Aptamers Market into the following categories:
By End User:
The MEA Aptamers Market is expected to account for a moderate share of the global market during the forecast period. The increasing level of research and development activities on Aptamers, the presence of key market players, and regaining economic growth in the developing countries in the region are augmenting the market growth. Countries such as South Africa, UAE, and Saudi Arabia will likely contribute to the MEA regional market growth. Research and Development, Therapeutics Development, Diagnostics, and Other Applications are some of the main applications that may be explored in the aptamers market. Due to key players' launch of innovative diagnostic kits, the "Diagnostics" category led the market in 2022 and is expected to retain its dominance by 2027.
The South African aptamers market is projected to account dominant share of the MEA Aptamers market during the forecast period. Advancements in aptamer development technologies, favorable reimbursement policies, and increasing R&D activities fuel market growth. In Addition, a rising number of companies are investing in the Aptamers market. Furthermore, the increasing prevalence of life-threatening illnesses such as cancer has prompted several firms to develop novel aptamer-based detection tests.
On the other hand, emerging countries such as UAE and Saudi Arabia are anticipated to showcase a promising share in the MEA Aptamers market in the coming future. In addition, the increasing number of companies investing in this market with the advent of new technologies in aptamers and Cost-effectiveness too plays a major role in supporting the market demand for Aptamers.
KEY MARKET PLAYERS:
Companies playing an active role in the Middle East & Africa aptamers market are AM Biotechnologies, Aptagen, Aptamer Sciences Inc., Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., SomaLogic Inc, TriLink BioTechnologies Inc., and Vivonics, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com